

SUPPLEMENTARY TABLE S2. INGENUITY PATHWAY ANALYSIS COMPARING CHRONIC GRANULOMATOUS DISEASE PATIENTS AND THE HEALTHY CONTROLS

<i>Pathway</i>	<i>-Log (p-value)</i>	<i>p-Value</i>	<i>n</i>	<i>Ratio</i>
B-cell development	4.59	2.6E-05	8	1.35E-01
Role of pattern recognition receptors in recognition of bacteria and viruses	3.93	1.2E-04	7	8.75E-02
Interferon signaling	3.03	9.3E-04	4	1.33E-01
B-cell receptor signaling	2.74	0.002	8	5.19E-02
Systemic lupus erythematosus signaling	2.58	0.003	7	4.35E-02
Oxidative phosphorylation	2.48	0.003	7	4.24E-02
IL-4 signaling	2.47	0.003	5	6.85E-02
Nonsmall cell lung cancer signaling	2.44	0.004	5	6.33E-02
Glioma signaling	2.40	0.004	6	5.36E-02
Altered T-cell and B-cell signaling in rheumatoid arthritis	2.12	0.008	5	5.49E-02
Citrate cycle	1.97	0.011	3	5.17E-02
Ubiquinone biosynthesis	1.80	0.016	4	3.36E-02
Antigen presentation pathway	1.78	0.017	3	7.69E-02
GM-CSF signaling	1.78	0.017	4	5.97E-02
Oncostatin M signaling	1.78	0.017	3	8.57E-02
Primary immunodeficiency signaling	1.72	0.019	3	4.76E-02
Fc γ RIIB signaling in B lymphocytes	1.66	0.022	3	5.36E-02
iCOS-iCOSL signaling in T helper cells	1.65	0.022	5	4.1E-02
PKC θ signaling in T lymphocytes	1.56	0.028	5	3.6E-02
Melanoma signaling	1.54	0.029	3	6.52E-02

n, the number of transcripts associated with the indicated pathway.